# Integration of pathway balance and protein fusion enables de novo biosynthesis of (+)-bicyclogermacrene in Escherichia coli

**Authors:** Chen-Yi Sun, Wen-Liang Xie, Zheng-Yu Huang, Chun-Xiu Li, Jian-He Xu

PMC · DOI: 10.1186/s40643-026-01017-4 · Bioresources and Bioprocessing · 2026-02-28

## TL;DR

Scientists engineered E. coli to produce a valuable compound called (+)-bicyclogermacrene, achieving the highest production levels ever reported.

## Contribution

The study reports the highest titer of (+)-bicyclogermacrene achieved through pathway balance and protein fusion in E. coli.

## Key findings

- Genome-integrated MEP pathway increased precursor flux, raising titer from 11.3 to 50.1 mg/L.
- Fusion of downstream genes and NADPH optimization boosted titer to 119 mg/L.
- Engineered E. coli strain M6-36 produced 565 mg/L in a bioreactor, a 50-fold increase.

## Abstract

(+)-Bicyclogermacrene and its derivatives, with promising antimicrobial, anticancer, and insecticidal properties, hold significant potential for applications in pharmaceuticals, agriculture, and industry. However, traditional extraction methods from plant essential oils are unsustainable. In this study, we achieved the de novo biosynthesis of (+)-bicyclogermacrene using a metabolically engineered Escherichia coli strain. The biosynthetic pathway of (+)-bicyclogermacrene was partitioned into upstream and downstream modules to enable precise regulation. This was accomplished through the genome-integrated overexpression of the endogenous methylerythritol phosphate pathway to ensure an adequate supply of terpenoid precursors, which pulled the titer from the initial 11.3 mg/L to 50.1 mg/L. Production was further enhanced to 96.9 mg/L by fusion of downstream key genes to facilitate precursor channeling, along with expression level optimization to improve pathway efficiency. Additionally, NADPH supply was fine-tuned through overexpressing dehydrogenases to improve the overall metabolic balance and this approach achieved a titer of 119 mg/L. Following site-directed of (+)-bicyclogermacrene synthase, the engineered E. coli strain M6-36 produced 565 mg/L of (+)-bicyclogermacrene in a 5-L bioreactor, an approximately 50-fold increase from the initial. To the best of our knowledge, the obtained titer in this study represents the highest level ever reported for the production of (+)-bicyclogermacrene. This study demonstrates an effective approach for the heterologous biosynthesis of sesquiterpenoids in E. coli and provides a scalable platform for the sustainable production of terpenoid-derived valuable chemicals.

The online version contains supplementary material available at 10.1186/s40643-026-01017-4.

Genome-integrated MEP pathway enlarges the flux of isoprenoid precursors.Protein expression levels were coordinated to improve the (+)-bicyclogermacrene production.Enzyme Engineering enables the highest de novo synthesis of (+)-bicyclogermacrene.

Genome-integrated MEP pathway enlarges the flux of isoprenoid precursors.

Protein expression levels were coordinated to improve the (+)-bicyclogermacrene production.

Enzyme Engineering enables the highest de novo synthesis of (+)-bicyclogermacrene.

The online version contains supplementary material available at 10.1186/s40643-026-01017-4.

## Linked entities

- **Chemicals:** (+)-bicyclogermacrene (PubChem CID 5315347)
- **Species:** Escherichia coli (taxon 562)

## Full-text entities

- **Genes:** idi (isopentenyl-diphosphate Delta-isomerase) [NCBI Gene 949020] {aka ECK2884, ygfV}, dxs (1-deoxy-D-xylulose-5-phosphate synthase) [NCBI Gene 945060] {aka ECK0414, yajP}, ispA (geranyl diphosphate/farnesyl diphosphate synthase) [NCBI Gene 945064] {aka ECK0415}
- **Diseases:** cytotoxic (MESH:D064420), inflammatory (MESH:D007249)
- **Chemicals:** IPP (MESH:C004809), NAD(H) (MESH:D009243), sulfuric acid (MESH:C033158), Thr (MESH:D013912), chloramphenicol (MESH:D002701), amorphadiene (MESH:C515348), glucose (MESH:D005947), FPP (MESH:C004808), IPTG (MESH:D007544), MEP (MESH:C114232), CO2 (MESH:D002245), ATP (MESH:D000255), ammonium hydroxide (MESH:D064753), Agarose (MESH:D012685), n-dodecane (MESH:C007548), 6-Phospho-gluconate (MESH:C008884), sesquiterpene (MESH:D012717), beta-carotene (MESH:D019207), CYS (MESH:D003545), (+)-2-carene (MESH:C113988), MgSO4 (MESH:D008278), NADP(H) (MESH:D009249), Ser (MESH:D012694), TCA (MESH:D014238), TB medium (-), FDP (MESH:C020332), glycerol (MESH:D005990), tetracycline (MESH:D013752), Fructose-1,6-Bisphosphate (MESH:C029063), alpha-ketoglutarate (MESH:D007656), Fructose-6- Phosphate (MESH:C027618), taxadiene (MESH:C093125), SDS (MESH:D012967), isoprene (MESH:C005059), Gly (MESH:D005998), kanamycin (MESH:D007612), Ribulose-5-Phosphate (MESH:C031524), malate (MESH:C030298), germacrene D (MESH:C027259), PEP (MESH:D010728), ED (MESH:D004540), isoprenoid (MESH:D013729), essential oils (MESH:D009822), acetyl-CoA (MESH:D000105), 1-Deoxy-D-xylulose 5-phosphate (MESH:C109460), Li (MESH:D008094), K2HPO4 (MESH:C013216), NH4Cl (MESH:D000643), Glucose-6-Phosphate (MESH:D019298), 2-keto-3-deoxy-6-phosphogluconate (MESH:C081217), isocitrate (MESH:C034219), pentose phosphate (MESH:D010428), polyacrylamide (MESH:C016679), Glyceraldehyde-3-Phosphate (MESH:D005986), streptomycin (MESH:D013307), carbon (MESH:D002244), glucose-1-phosphate (MESH:C031590), NaCl (MESH:D012965), MVA (MESH:D008798), pyruvate (MESH:D019289)
- **Species:** Escherichia coli str. K-12 substr. MG1655 (no rank) [taxon 511145], Eugenia gracillima (species) [taxon 2364051], Micromonospora sp. 6 (species) [taxon 1043610], Matricaria chamomilla var. recutita (German chamomile, varietas) [taxon 127986], Escherichia coli DH5[alpha] (strain) [taxon 668369], Penicillium expansum (species) [taxon 27334], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Ageratum conyzoides (species) [taxon 68299], Escherichia coli (E. coli, species) [taxon 562]
- **Mutations:** E207P, C at 10, L352F, C at 20, G91S
- **Cell lines:** M6-36 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_DH73), MG1655 — Homo sapiens (Human), Maple syrup urine disease, Transformed cell line (CVCL_D514), M6-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_G077), -12 — Mus musculus (Mouse), Hybridoma (CVCL_J992), K-12 — Felis catus (Cat), Feline mammary carcinoma, Cancer cell line (CVCL_IX41), M6-30 — Homo sapiens (Human), Transformed cell line (CVCL_B4JP)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950146/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950146/full.md

---
Source: https://tomesphere.com/paper/PMC12950146